Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 studyGiuseppe Saglio, Hervé Dombret, M. Brigid Bradley‐Garelik et al.|Cancer|2010Cited by 125